ELI LILLY AND COMPANY OCI, before Reclassifications, Net of Tax, Attributable to Parent
ELI LILLY AND COMPANY (LLY) reported OCI, before Reclassifications, Net of Tax, Attributable to Parent of $499.40 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-01.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent · last filed 2025-05-01
- ELI LILLY AND COMPANY oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2025-03-31 was $499.40M.
- ELI LILLY AND COMPANY oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2024-03-31 was -$5.40M.
- ELI LILLY AND COMPANY oci, before reclassifications, net of tax, attributable to parent for fiscal 2024 was -$98.60M.
- ELI LILLY AND COMPANY oci, before reclassifications, net of tax, attributable to parent for fiscal 2023 was -$518.20M, a 309.20% decline from fiscal 2022.
- ELI LILLY AND COMPANY oci, before reclassifications, net of tax, attributable to parent for fiscal 2022 was $247.70M, a 86.20% decline from fiscal 2021.
- ELI LILLY AND COMPANY oci, before reclassifications, net of tax, attributable to parent for fiscal 2021 was $1.80B.
| Period end | OCI, before Reclassifications, Net of Tax, Attributable to Parent 3 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 12 month |
|---|---|---|
| 2025-03-31 | $499.40M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | -$98.60M 10-K · filed 2025-02-19 | |
| 2024-03-31 | -$5.40M 10-Q · filed 2025-05-01 | |
| 2023-12-31 | -$518.20M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $247.70M 10-K · filed 2025-02-19 | |
| 2021-12-31 | $1.80B 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |